Pomerantz LLP is investigating Beam Therapeutics and some of its executives for potential securities fraud following a press release on September 8, 2026. The release shared updated clinical trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency, noting safety issues including transient liver enzyme elevations. This news caused Beam's stock to fall nearly 10% in one day. The investigation could lead to a class action lawsuit if wrongdoing is found.
The story concerns Beam Therapeutics Inc. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: Among 91 health-sector US stocks priced on Pluang, 59 rose and 31 fell today. Notably, BioNano Genomics Inc (BNGO) gained 9.27% to USD 1.65 with a typical hold time of 49 days, while Novavax Inc (NVAX) rose 8.77% to USD 10.17, attracting 100% buy order activity and a longer hold time of 59 days. Meanwhile, 10X Genomics Inc (TXG) increased 8.02% to USD 78.51 with balanced buy-sell orders and the longest hold time of 94 days among these movers.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
